文献速递冠心病

无保护左主干病变:延迟治疗、搭桥与介入的临床结局比较

Unprotected Left Main Disease: Clinical Outcomes Following Deferral, Coronary Artery Bypass Grafting, or Percutaneous Coronary Intervention
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-09-21

本研究利用西丹麦心脏注册研究数据,纳入2002年1月至2021年1月因慢性冠状动脉综合征行冠脉造影发现孤立性无保护左主干病变的患者4848例,分为延迟≤50%狭窄、延迟>50%狭窄、PCI和CABG四组。结果显示左主干直径狭窄超过50%时,PCI或CABG均与生存改善相关。

要点

  • 左主干狭窄>50%的慢性冠脉综合征患者,血运重建与生存改善相关。
  • PCI较CABG非致死性ACS和再次血运重建率更高,但与延迟治疗相似。
  • 显著无保护左主干病变应优先考虑血运重建以改善预后。

核心结论

  • 利用真实世界数据表明,左主干直径狭窄超过50%时,PCI或CABG均与患者生存改善相关。
  • PCI与CABG相比非致死性ACS和再次血运重建率更高,但与延迟治疗组发生率相似。

研究设计与样本

  • 研究纳入西丹麦心脏注册研究中2002年1月至2021年1月因慢性冠状动脉综合征行冠脉造影发现孤立性无保护左主干病变的患者4848例。
  • 患者分为四组:延迟≤50%狭窄组992例,延迟>50%狭窄组570例,PCI组2819例,CABG组467例。

主要发现

  • 5年生存概率:PCI组89.5%,CABG组94.1%,延迟≤50%组91.7%,延迟>50%组84.0%(p<0.0005%)。
  • ACS累积发生率:PCI组7.9%,CABG组3.0%,延迟≤50%组5.3%,延迟>50%组8.2%(p<0.0005)。
  • 再次血运重建率:PCI组10.2%,CABG组7.0%,延迟≤50%组7.6%,延迟>50%组15.4%(p<0.0005)。
  • 卒中发生率:PCI组3.6%,CABG组2.1%,延迟≤50%组2.5%,延迟>50%组3.8%(p<0.005)。
  • 校正分析后上述结果未发生改变。

关键数值与推荐

  • 左主干直径狭窄>50%为显著狭窄的血运重建界值。
  • 5年生存概率:PCI组89.5%,CABG组94.1%,延迟≤50%组91.7%,延迟>50%组84.0%(p<0.0005%)。
  • ACS累积发生率:PCI组7.9%,CABG组3.0%,延迟≤50%组5.3%,延迟>50%组8.2%(p<0.0005)。

临床怎么用

  • 慢性冠状动脉综合征合并无保护左主干直径狭窄>50%的患者,建议进行血运重建治疗。
  • CABG与PCI相比非致死性ACS和再次血运重建率更低,临床决策时应个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background The prognostic benefit of revascularization for unprotected left main (LM) disease remains uncertain, as guideline endorsement of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) precludes comparison with deferral, which is unlikely to be assessed in a randomized trial. Objectives This study aimed to evaluate the prognostic impact of revascularization (PCI/CABG) versus deferred treatment of isolated, unprotected LM disease using real-world data. Methods Patients with isolated, unprotected LM disease identified by invasive coronary angiography on the indication chronic coronary syndrome between January 2002 and January 2021, registered in the Western Denmark Heart Registry, were identified and split into four groups: Defer ≤ 50% stenosis, defer > 50% stenosis, PCI, or CABG. Acute coronary syndrome (ACS), revascularization, stroke, and all-cause mortality risks within 5 years were assessed. Adjusted analyses were conducted. Results Of 4848 patients identified, 2819 patients underwent PCI, 467 CABG, 992 were in the defer ≤ 50% group, and 570 in defer > 50%. The 5-year survival probability was 89.5% for PCI, 94.1% for CABG, 91.7% for defer ≤ 50%, and 84.0% for defer > 50% (p < 0.0005%). Cumulative incidence of ACS was 7.9% for PCI, 3.0% for CABG, 5.3% for defer ≤ 50%, and 8.2% for defer > 50% (p < 0.0005). For revascularization, numbers were 10.2%, 7.0%, 7.6%, and 15.4% (p < 0.0005) and stroke 3.6%, 2.1%, 2.5%, and 3.8% (p < 0.005). In adjusted analyses, the results were unchanged. Conclusions Using real-world data, this study demonstrated that either PCI or CABG was associated with improved survival in patients with LM disease, when diameter stenosis exceeded 50%. PCI was associated with higher rates of non-fatal ACS and repeat revascularization compared to CABG but similar rates as deferred treatment. Clinical Perspectives The prognostic benefit of revascularization for isolated and unprotected left main disease remains uncertain, as guideline endorsement of PCI or CABG precludes comparison with deferral. Deferred revascularization of unprotected LM disease with >50% diameter stenosis in patients with chronic coronary syndrome was associated with increased all-cause mortality and non-fatal acute coronary syndrome. Revascularization remains the treatment of choice in patients with significant unprotected LM disease for prognostic benefit.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Unprotected Left Main Disease: Clinical Outcomes Following Deferral, Coronary Artery Bypass Grafting, or Percutaneous Coronary Intervention

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。